TAGline Fall 2018: Intellectual property and access

As the Trump administration makes noise about  the high price of pharmaceuticals while doubling down on its commitment to “protect the engine of American ingenuity,” this issue of TAGline dives deep into the rhetoric and realities of intellectual property  (IP)  protections  and  the current wave of political shenanigans on critical drugs, surfacing the fundamental lies and vested interests that deny medication to those in need in the United States and around the world.

In this issue of TAGline:

• Whose Intellect? Whose Property?
  A Blueprint for Bringing Down the Pharma IP House of Cards
  By JD Davids, TAGline Guest Editor and Suraj Madoori, U.S. and Global Health Policy Director, TAG
• Beyond Declarations:
  Lessons from the UN High-Level Meeting on TB on Building and Transforming Political Will into Real Access to Medicines
  By Khairunisa Suleiman, Co-Technical Lead, Global TB CAB and Suraj Madoori, U.S. and Global Health Policy Director, TAG
• Fierce Activism from the Global Access to Medicines (A2M) Movement:
  Reflections on Recent Sucess
  By Bryn Gay, HCV Project Director, TAG
• Getting Rid of the Boogeyman:
  The Reality of Prescription Drug Price Controls
  By Annette Gaudino, HCV/HIV Project Co-Director, TAG
• Keeping an Eye on Intellectual Property Issues in HIV Cure and Prevention Research
  By Richard Jefferys, Basic Science, Vaccines, and Cure Project Director, TAG
• Pharma Lies, People Die:
  Myth-Busting Fact Sheet on Medicine Development and Pricing
  By Bryn Gay, HCV Project Director, Tag and Claudine Guerra, CUNY
• A Pharma View on Delinkage and New Models for Biomedical Innovation:
  An Interview with Marc Destito From Otsuka Pharmaceutical
  By Mike Frick and Lindsay McKenna, TB Project Co-Directors, TAG

Download TAGline Fall 2018

Source: Treatment Action Group